5
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Ototoxic Effect of Potassium Canrenoate on the Guinea Pig Cochlea

, , , , &
Pages 719-727 | Received 15 Oct 1990, Accepted 30 Nov 1990, Published online: 08 Jul 2009
 

Abstract

Potassium canrenoate (PC) is a diuretic with antialdosterone action, reducing the reabsorp-tion of sodium in the efferent renal tubules. This drug has been reported to damage only the marginal cells of the stria vascularis in the cochlea. the perilymphatic space of the guinea pig cochlea was perfused with an artificial perilymph containing 5×l0∼3 M potassium canrenoate. Following the onset of perfusion, the endocochlear dc potential (EP) gradually declined to around 10 mV but did not become negative even when the perfusion was continued. a similar decrease in EP was observed in kanamycin-deafened guinea pigs. When the respirator was turned off and perfusion discontinued, a large negative EP appeared during 5 min of anoxia in normal guinea pigs but not in the kanamycin-deafened guinea pigs. the decreased EP recovered to preanoxic level after resumption of ventilation. the cochlear microphonics (CM) also gradually declined in parallel with the EP. the summating potential (SP) showed only a minor change. the potassium ion activity in the endolymph decreased slightly but the sodium ion activity remained unchanged during perfusion. These findings suggest that the main target of the PC is the cells of the stria vascularis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.